Eli Lilly Proposes $6.75 Cash Plus CVR Acquisition of ATAI, Law Firm Investigates Deal Adequacy

What happened

Eli Lilly and Company has agreed to acquire ATAI Life Sciences for $6.75 per share in cash plus a contingent value right of up to $2.50 per share, according to a Business Wire announcement dated August 17, 2026. The law firm Kahn Swick & Foti is investigating whether the price and process are adequate for shareholders, signaling potential legal challenges to the proposed sale. The latest DeepValue master report, dated July 2, 2026, rated ATAI a 'Wait' with a base scenario value of $5.80, a bear case of $3.40, and a bull case of $6.80, based primarily on BPL-003 Phase 3 execution milestones. The Eli Lilly offer of $6.75 cash (excluding CVR) already exceeds the base case and approaches the bull case, suggesting the market may have undervalued ATAI's pipeline or that Lilly sees strategic value beyond the near-term clinical timeline. The CVR adds potential upside but introduces uncertainty tied to future milestone payments, making the total consideration range from $6.75 to $9.25 per share.

Implication

The Eli Lilly offer shifts ATAI's investment thesis from clinical execution risk to deal completion and fairness risk, with the cash portion providing a near-term floor while the CVR's value depends on uncertain future milestones. Shareholders should scrutinize the CVR's specific terms, as the full $2.50 payout may require achieving significant clinical or regulatory targets that could be years away. The law firm's investigation suggests some institutional holders or analysts believe the price may be inadequate, potentially leading to a higher offer or improved terms. The DeepValue report's focus on Phase 3 BPL-003 enrollment transparency becomes less critical for near-term value, as the acquisition would likely truncate the standalone timeline. Risk assessment should now weigh merger arbitrage dynamics, including regulatory approval, shareholder vote, and potential competing bids, against the opportunity cost of holding through a lengthy sale process.

Thesis delta

The prior standalone thesis, predicated on BPL-003 Phase 3 execution and cash burn management, is superseded by the announced acquisition proposal from Eli Lilly. The value proposition now centers on the merger consideration (cash plus CVR) rather than long-term clinical milestones, shifting the analysis to deal fairness and completion probability. Investors should revise expectations accordingly, as the 'Wait' rating and scenario valuations no longer reflect the controlling reality of a potential exit at a defined price range.